Stephen J. Blakemore

2.4k citations

47 papers · 1.4k indexed · 1 hit paper · h-index 17

Impact in

Hematology top 5%
- Acute Myeloid Leukemia Research
Molecular Biology top 10%
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Cancer-related gene regulation
- Chromatin Remodeling and Cancer

Papers in

Hematology 10
- Acute Myeloid Leukemia Research 8
Molecular Biology 35
- Ubiquitin and proteasome pathways 11
- Protein Degradation and Inhibitors 9
- Cancer-related gene regulation 8
- Chromatin Remodeling and Cancer 6
- Epigenetics and DNA Methylation 4

Co-authors: Peter Ho Blythe Thomson Antoîne Italiano Alice McDonald Alicia Clawson Scott Ribich Vincent Ribrag Jean‐Marie Michot
Journals: Molecular Cancer Therapeutics (8 papers)Cancer Research (8 papers)Journal of Clinical Oncology (7 papers)Blood (7 papers)European Journal of Cancer (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Stephen J. Blakemore

40 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study 2018 · 451 citations

Peers

Countries citing papers authored by Stephen J. Blakemore

Since Specialization

Citations

This map shows the geographic impact of Stephen J. Blakemore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen J. Blakemore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen J. Blakemore more than expected).

Fields of papers citing papers by Stephen J. Blakemore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen J. Blakemore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen J. Blakemore. The network helps show where Stephen J. Blakemore may publish in the future.

Co-authors

The 25 scholars most cited alongside Stephen J. Blakemore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen J. Blakemore Line = papers co-authored together Stephen J. Blakemore links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement ACS Medicinal Chemistry Letters ·Brian A. Sparling, Hyelee Lee, Mary-Margaret Zablocki, Maureen M. Lynes, Simina Grigoriu, Livia Shehaj, G.J. Lockbaum, Sanjoy Khan, Taylor Hotz, Young‐Tae Lee, Shane M. Buker, Deepali Gotur, Chuang Lu, Scott Ribich, Stephen J. Blakemore, P. Ann Boriack‐Sjodin, Serena J. Silver, Robert A. Copeland, Kenneth W. Duncan	2025	0
2	Abstract PR003: DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2 Cancer Research ·Jennifer Castro, Matthew H. Daniels, Sunaina Pai, Monique Laidlaw, Jie Wu, David Brennan, Brian Johnston, Anugraha Raman, Chuang Lu, Stephen J. Blakemore, Serena J. Silver, P. Ann Boriack‐Sjodin, Kenneth W. Duncan, Jason A. Sager, Robert A. Copeland	2024	0
3	Abstract 333: Activity of the erythropoietin-producing hepatocellular A2 receptor (EphA2) targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR inhibitor resistant non-small lung cancer (NSCLC) patient derived xenografts Cancer Research ·Kenneth Ngo, Elena V. Ivanova, Tyler J. Teceno, Carly Campbell, Johanna Lahdenranta, Stephen J. Blakemore, Gavin Bennett, Pasi A. Jänne, Cloud P. Paweletz, Prafulla C. Gokhale	2022	0
4	BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism Journal for ImmunoTherapy of Cancer ·Kristen E. Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Elizabeth Repash, Drasti Kanakia, Jun Ma, Julia Kristensson, Fanglei You, Carly Campbell, David R. Witty, Mike Kelly, Stephen J. Blakemore, Phil Jeffrey, Kevin McDonnell, Philip E. Brandish, Nicholas Keen	2021	25
5	Abstract 1197: A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection Cancer Research ·Carly Campbell, Robert Smale, Michael Rigby, Shawn Watson, Amy L. Dickson, Tara Gelb, Heather Cohen, Pierre Lee, Josette William Ragheb, Stephen J. Blakemore	2021	1
6	Abstract A047: MT1-MMP Immunohistochemistry (IHC) analysis of tumor microarrays (TMAs) using a novel scoring system guides patient selection for BT1718 expansion cohorts Molecular Cancer Therapeutics ·Tara Gelb, Chris M. Bacon, Philip Sloan, Mike Rigby, Stephanie Guerrera, Fiona Kelly, Stefan N. Symeonides, Stephen J. Blakemore	2019	1
7	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study The Lancet Oncology ·Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde, Jean‐Marie Michot, Carlo Lucchesi, Andréa Varga, Jean‐Michel Coindre, Stephen J. Blakemore, Alicia Clawson, Benjamin Suttle, Alice McDonald, Mark Woodruff, Scott Ribich, Eric Hedrick, Heike Keilhack, Blythe Thomson, Takashi Owa, Robert A. Copeland, Peter Ho, Vincent Ribrag Hit paper breakdown →	2018	451
8	Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950) Annals of Oncology ·Scott R. Daigle, Silvia Stacchiotti, Patrick Schöffski, Víctor M. Villalobos, Gregory M. Coté, Rashmi Chugh, T.W.-W. Chen, Thierry Jahan, Elizabeth T. Loggers, Antoîne Italiano, Abha A. Gupta, Mark Agulnik, Steven Attia, Robin L. Jones, Brian A. Van Tine, George D. Demetri, Alicia Clawson, Maria Roche, Stephen J. Blakemore, Mrinal M. Gounder	2018	4
9	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Blood ·Vincent Ribrag, Franck Morschhauser, Pam McKay, Gilles Salles, Connie Lee Batlevi, Anna Schmitt, Hervé Tilly, Guillaume Cartron, Catherine Thiéblemont, Christophe Fruchart, John G. Gribben, Thierry Lamy, Steven Le Gouill, Réda Bouabdallah, Michael Dickinson, Stephen Opat, Deyaa Adib, Stephen J. Blakemore, John Larus, Peter Johnson	2018	15
10	Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia Molecular Cancer Therapeutics ·Carly Campbell, Jessica N. Haladyna, David A. Drubin, Timothy M. Thomson, Michael J. Maria, Taylor Yamauchi, Nigel J. Waters, Edward J. Olhava, Roy M. Pollock, J. Joshua Smith, Robert A. Copeland, Stephen J. Blakemore, Kathrin M. Bernt, Scott R. Daigle	2017	46
11	Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology ·Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoîne Italiano, Robin L. Jones, George D. Demetri, Stephen J. Blakemore, Alicia Clawson, Scott R. Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter Ho, Gregory M. Coté	2017	23
12	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) Investigational New Drugs ·Kit Man Wong, Lindsey N. Micel, Heather M. Selby, Aik Choon Tan, Todd M. Pitts, Stacey M. Bagby, Anna Spreafico, Peter J. Klauck, Stephen J. Blakemore, Peter F. Smith, Alice McDonald, Allison Berger, John J. Tentler, Sabine Eckhardt	2016	16
13	Phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology ·Franck Morschhauser, Gilles Salles, Steven Le Gouill, John Radford, Pam McKay, Guillaume Cartron, Patricia Pimentel, Maria Roche, Stephen J. Blakemore, Alice McDonald, Natalie M. Warholic, Shelley Knight, Peter Ho, Vincent Ribrag	2016	10
14	Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition Blood ·Neerav Shukla, Maureen M. O’Brien, Lewis B. Silverman, Melinda Pauly, Cynthia Wetmore, Mignon L. Loh, James A. Whitlock, Patrick A. Brown, Blythe Thomson, Stephen J. Blakemore, Scott R. Daigle, Patricia Pimentel, Nigel J. Waters, Andrei V Krivstov, Richard P. Koche, Scott A. Armstrong, Peter Ho, Lia Gore	2015	10
15	Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in MLL-rearranged leukemia cell lines Molecular Cancer Therapeutics ·Alejandra Raimondi, Christine R. Klaus, Jeffrey Keats, Scott R. Daigle, Robert A. Copeland, Jorge DiMartino, J. Joshua Smith, Stephen J. Blakemore	2015	2
16	Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer Clinical Cancer Research ·Steffan T. Nawrocki, Kevin R. Kelly, Peter G. Smith, Claudia M. Espitia, Anthony Possemato, Sean A. Beausoleil, Michael A. Milhollen, Stephen J. Blakemore, Michaël Thomas, Allison Berger, Jennifer S. Carew	2013	89
17	1210 POSTER Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results European Journal of Cancer ·P Smith, J. R. Infante, L.L. Siu, Dan M. Sullivan, Gordana Vlahovic, John Kauh, Stephen J. Blakemore, Neeraj Gupta, Thea Kalebic, J.A. Thompson	2011	2
18	Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693 BMC Genomics ·Rakesh Kumar, Stephen J. Blakemore, Catherine Ellis, Emanuel F. Petricoin, Dexter Pratt, Michael Macoritto, Andrea Matthews, Joseph Loureiro, Keith Elliston	2010	27
19	Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: Further evidence for the inflammatory basis of atherosclerosis American Heart Journal ·Gemma Satterthwaite, Sheila Francis, Kim Suvarna, Stephen J. Blakemore, Chantelle Ward, Don Wallace, Martin Braddock, David C. Crossman	2005	43
20	GLUT5 Expression and Fructose Transport in Human Skeletal Muscle Advances in experimental medicine and biology ·Harinder S. Hundal, Froogh Darakhshan, Søren Kristiansen, Stephen J. Blakemore, Erik A. Richter	1998	23

About Stephen J. Blakemore

Stephen J. Blakemore is a scholar working on Hematology, Molecular Biology, Pathology and Forensic Medicine, Cancer Research and Oncology, having authored 47 papers that have together received 1.4k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (11 papers), Protein Degradation and Inhibitors (9 papers), Acute Myeloid Leukemia Research (8 papers), Cancer-related gene regulation (8 papers), Chromatin Remodeling and Cancer (6 papers), Cancer Mechanisms and Therapy (5 papers), Peptidase Inhibition and Analysis (5 papers) and Epigenetics and DNA Methylation (4 papers). The work is most often cited by research in Hematology (184 citations), Molecular Biology (969 citations), Oncology (339 citations), Pathology and Forensic Medicine (201 citations) and Cancer Research (135 citations). Stephen J. Blakemore has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Peter Ho, Blythe Thomson, Antoîne Italiano, Alice McDonald, Alicia Clawson, Scott Ribich, Vincent Ribrag, Jean‐Marie Michot, Robert A. Copeland and Heike Keilhack. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Journal of Clinical Oncology, Blood and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact